Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Impact · against what's priced in

Wenda Pharma receives a positive catalyst from Phase II data for NHWD-870 HCl, which shows a 30% ORR and an OS of 9.33 months against a 6.7-month benchmark. Additionally, the completion of Phase III enrollment for WD-890 suggests a nearing data readout for its plaque psoriasis candidate.

Scored by the NIS engine · methodology.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

clinical trials▲106%
biotech

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027